777 related articles for article (PubMed ID: 10395479)
1. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Spicer JA; Gamage SA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1997 Jun; 40(12):1919-29. PubMed ID: 9191970
[TBL] [Abstract][Full Text] [Related]
3. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
Spicer JA; Finlay GJ; Baguley BC; Velea L; Graves DE; Denny WA
Anticancer Drug Des; 1999 Feb; 14(1):37-45. PubMed ID: 10363026
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
Deady LW; Kaye AJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1997 Jun; 40(13):2040-6. PubMed ID: 9207945
[TBL] [Abstract][Full Text] [Related]
5. Bis(phenazine-1-carboxamides): structure-activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs.
Spicer JA; Gamage SA; Rewcastle GW; Finlay GJ; Bridewell DJ; Baguley BC; Denny WA
J Med Chem; 2000 Apr; 43(7):1350-8. PubMed ID: 10753472
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
7. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
8. Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
Antonini I; Polucci P; Magnano A; Sparapani S; Martelli S
J Med Chem; 2004 Oct; 47(21):5244-50. PubMed ID: 15456268
[TBL] [Abstract][Full Text] [Related]
9. Dimeric analogues of non-cationic tricyclic aromatic carboxamides are a new class of cytotoxic agents.
Spicer JA; Gamage SA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
Anticancer Drug Des; 1999 Jun; 14(3):281-9. PubMed ID: 10500503
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological properties of new bis(acridine-4-carboxamides) as anticancer agents.
Antonini I; Polucci P; Magnano A; Gatto B; Palumbo M; Menta E; Pescalli N; Martelli S
J Med Chem; 2003 Jul; 46(14):3109-15. PubMed ID: 12825949
[TBL] [Abstract][Full Text] [Related]
11. Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.
Gamage SA; Spicer JA; Finlay GJ; Stewart AJ; Charlton P; Baguley BC; Denny WA
J Med Chem; 2001 Apr; 44(9):1407-15. PubMed ID: 11311063
[TBL] [Abstract][Full Text] [Related]
12. Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Haldane A; Finlay GJ; Hay MP; Denny WA; Baguley BC
Anticancer Drug Des; 1999 Jun; 14(3):275-80. PubMed ID: 10500502
[TBL] [Abstract][Full Text] [Related]
13. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
[TBL] [Abstract][Full Text] [Related]
14. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
16. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
17. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
[TBL] [Abstract][Full Text] [Related]
18. 4-Hydroxymethyl-3-aminoacridine derivatives as a new family of anticancer agents.
Charmantray F; Demeunynck M; Carrez D; Croisy A; Lansiaux A; Bailly C; Colson P
J Med Chem; 2003 Mar; 46(6):967-77. PubMed ID: 12620073
[TBL] [Abstract][Full Text] [Related]
19. Oxiranylmethyloxy or thiiranylmethyloxy-azaxanthones and -acridone analogues as potential topoisomerase I inhibitors.
Cho HJ; Jung MJ; Kwon Y; Na Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6766-9. PubMed ID: 19836231
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
Deady LW; Rodemann T; Zhuang L; Baguley BC; Denny WA
J Med Chem; 2003 Mar; 46(6):1049-54. PubMed ID: 12620081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
